GI Alliance

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis	Moderately to Severely Active Ulcerative Colitis	Active, not recruiting	Phase 3	2026-10-02	NCT06588855
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease	Moderately to Severely Active Crohns Disease	Recruiting	Phase 3	2026-09-28	NCT06819891
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis	Moderately to Severely Active Ulcerative Colitis	Active, not recruiting	Phase 3	2026-09-14	NCT06589986
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)	Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis	Active, not recruiting	Phase 3	2026-04-20	NCT03519945

Clinical trials